- advanced neuroendocrine tumors
- delphi technique
- Octreotide LAR
- second-line therapy
- antineoplastic agent
- antineoplastic hormone agonists and antagonists
- delayed release formulation
- neuroendocrine tumor
- practice guideline
- Antineoplastic Agents, Hormonal
- Antineoplastic Combined Chemotherapy Protocols
- Delayed-Action Preparations
- Neuroendocrine Tumors
- Practice Guidelines as Topic
- Surveys and Questionnaires
Access to Document
FingerprintDive into the research topics of 'Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey: Expert Opinion on Pharmacotherapy'. Together they form a unique fingerprint.
Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey : Expert Opinion on Pharmacotherapy. / Falconi, M.; Fazio, N.; Ferone, D.; Versari, A.In: Expert Opin. Pharmacother., Vol. 21, No. 18, 2020, p. 2317-2324.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey
T2 - Expert Opinion on Pharmacotherapy
AU - Falconi, M.
AU - Fazio, N.
AU - Ferone, D.
AU - Versari, A.
N1 - Export Date: 3 March 2021 CODEN: EOPHF Correspondence Address: Falconi, M.; Pancreatic Surgery Division, Italy; email: firstname.lastname@example.org Chemicals/CAS: everolimus, 159351-69-6; octreotide, 83150-76-9, 1607842-55-6; Antineoplastic Agents, Hormonal; Delayed-Action Preparations; Everolimus; Octreotide Funding text 1: Writing and editing support utilized in this manuscript and was provided by Content Ed Net, with the helpful assistance of Patrick Moore of Adriatic Health Communications and was funded by Novartis Farma. The authors would also like to thank following experts for their participation: Giuseppe Badalamenti, Alfredo Berruti, Antonio Bianchi, Davide Campana, Sara Cingarlini, Antoniogiulio Faggiano, Dario Giuffrida, Sara Massironi, Francesco Panzuto, Sara Pusceddu, Nando Riccardi, Salvatore Tafuto, and Maria Chiara Zatelli. References: Rindi, G., Klimstra, D.S., Abedi-Ardekani, B., A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal (2018) Mod Pathol, 31 (12), pp. 1770-1786; Modlin, I.M., Oberg, K., Chung, D.C., Gastroenteropancreatic neuroendocrine tumours (2008) Lancet Oncol, 9 (1), pp. 61-72; Rubin de Celis Ferrari, A.C., Glasberg, J., Riechelmann, R.P., Carcinoid syndrome: update on the pathophysiology and treatment (2018) Clinics (Sao Paulo), 73, p. e490s; van der Zwan, J.M., Trama, A., Otter, R., Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project (2013) Eur J Cancer, 49 (11), pp. 2565-2578; Dasari, A., Shen, C., Halperin, D., Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States (2017) JAMA Oncol, 3 (10), pp. 1335-1342; Partelli, S., Giannone, F., Schiavo Lena, M., Is the real prevalence of pancreatic neuroendocrine tumors underestimated? A retrospective study on a large series of pancreatic specimens (2019) Neuroendocrinology, 109 (2), pp. 165-170; Guillemin, R., Gerich, J.E., Somatostatin: physiological and clinical significance (1976) Annu Rev Med, 27, pp. 379-388; Hofland, L.J., Lamberts, S.W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocr Rev, 24 (1), pp. 28-47; Reubi, J.C., Hacki, W.H., Lamberts, S.W., Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors (1987) J Clin Endocrinol Metab, 65 (6), pp. 1127-1134; Bauer, W., Briner, U., Doepfner, W., SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action (1982) Life Sci, 31 (11), pp. 1133-1140; Kvols, L.K., Moertel, C.G., O’Connell, M.J., Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue (1986) N Engl J Med, 315 (11), pp. 663-666; Saltz, L., Trochanowski, B., Buckley, M., Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors (1993) Cancer, 72 (1), pp. 244-248; Modlin, I.M., Pavel, M., Kidd, M., Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours (2010) Aliment Pharmacol Ther, 31 (2), pp. 169-188; Rinke, A., Muller, H.H., Schade-Brittinger, C., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group (2009) J Clin Oncol, 27 (28), pp. 4656-4663; Pavel, M.E., Hainsworth, J.D., Baudin, E., Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study (2011) Lancet, 378 (9808), pp. 2005-2012; Pusceddu, S., Prinzi, N., Raimondi, A., Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: a review of current knowledge (2019) Tumori, 105 (2), pp. 113-120; Caplin, M.E., Pavel, M., Cwikla, J.B., Lanreotide in metastatic enteropancreatic neuroendocrine tumors (2014) N Engl J Med, 371 (3), pp. 224-233; Pavel, M., O’Toole, D., Costa, F., ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site (2016) Neuroendocrinology, 103 (2), pp. 172-185; Loblaw, D.A., Prestrud, A.A., Somerfield, M.R., American society of clinical oncology clinical practice guidelines: formal systematic review-based consensus methodology (2012) J Clin Oncol, 30 (25), pp. 3136-3140; Fehr, A., Thurmann, P., Razum, O., Expert Delphi survey on research and development into drugs for neglected diseases (2011) BMC Health Serv Res, 11, p. 312; Stewart, D., Gibson-Smith, K., MacLure, K., A modified Delphi study to determine the level of consensus across the European Union on the structures, processes and desired outcomes of the management of polypharmacy in older people (2017) PLoS One, 12 (11); Deppen, S.A., Blume, J., Bobbey, A.J., 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis (2016) J Nucl Med, 57 (6), pp. 872-878; Lamberti, G., Faggiano, A., Brighi, N., Nonconventional doses of somatostatin analogs in patients with progressing well-differentiated neuroendocrine tumor (2020) J Clin Endocrinol Metab, 105 (1), pp. 194-200; Chan, D.L., Ferone, D., Albertelli, M., Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review (2017) Endocrine, 57 (3), pp. 366-375; Strosberg, J., El-Haddad, G., Wolin, E., Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors (2017) N Engl J Med, 376 (2), pp. 125-135; Strosberg, J., Wolin, E., Chasen, B., Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial (2018) J Clin Oncol, 36 (25), pp. 2578-2584; Lee, L., Ito, T., Jensen, R.T., Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence (2018) Expert Opin Pharmacother, 19 (8), pp. 909-928; Yao, J.C., Lombard-Bohas, C., Baudin, E., Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial (2010) J Clin Oncol, 28 (1), pp. 69-76; Yao, J.C., Shah, M.H., Ito, T., Everolimus for advanced pancreatic neuroendocrine tumors (2011) N Engl J Med, 364 (6), pp. 514-523; Pavel, M.E., Baudin, E., Oberg, K.E., Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (2017) Ann Oncol, 28 (7), pp. 1569-1575; Capdevila, J., Teule, A., Barriuso, J., Phase II study of everolimus and octreotide LAR in patients with nonfunctioning gastrointestinal neuroendocrine tumors: the GETNE1003_EVERLAR study (2019) Oncologist, 24 (1), pp. 38-46; Ferolla, P., Brizzi, M.P., Meyer, T., Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial (2017) Lancet Oncol, 18 (12), pp. 1652-1664; Yao, J.C., Pavel, M., Lombard-Bohas, C., Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study (2016) J Clin Oncol, 34 (32), pp. 3906-3913; Shah, M.H., Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial Poster presented at 2011 ASCO Annual Meeting, , June, 3-7, Chicago, IL, USA; Bajetta, E., Catena, L., Fazio, N., Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study (2014) Cancer, 120 (16), pp. 2457-2463; Bajetta, E., Catena, L., Pusceddu, S., Everolimus in combination with octreotide LAR in first line setting for patients with neuroendocrine tumors: a 5-years update (2018) Neuroendocrinology; Panzuto, F., Rinzivillo, M., Fazio, N., Real-world study of everolimus in advanced progressive neuroendocrine tumors (2014) Oncologist, 19 (9), pp. 966-974; Pavel, M., Oberg, K., Falconi, M., Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up (2020) Ann Oncol, 31 (7), pp. 844-860; Ge, W., Zhou, D., Zhu, L., Efficacy and safety of everolimus plus somatostatin analogues in patients with neuroendocrine tumors (2018) J Cancer, 9 (24), pp. 4783-4790; Kaderli, R.M., Spanjol, M., Kollar, A., Therapeutic options for neuroendocrine tumors: a systematic review and network meta-analysis (2019) JAMA Oncol, 5 (4), pp. 480-489; Grozinsky-Glasberg, S., Franchi, G., Teng, M., Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line (2008) Neuroendocrinology, 87 (3), pp. 168-181; Salazar, R., Reidy-Lagunes, D., Yao, J., Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer (2011) Drugs, 71 (7), pp. 841-852; Strosberg, J., Kunz, P.L., Hendifar, A., Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with (177)Lu-Dotatate: an analysis of the NETTER-1 study (2020) Eur J Nucl Med Mol Imaging, 47, pp. 2372-2382; Yordanova, A., Wicharz, M.M., Mayer, K., The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy (2018) Clin Cancer Res, 24 (19), pp. 4672-4679; Prasad, V., Srirajaskanthan, R., Toumpanakis, C., Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice (2020) Eur J Nucl Med Mol Imaging, 47 (10), pp. 2358-2371; Mayer, K., Kiry, S., Yordanova, A., Systemic therapy of neuroendocrine neoplasia: single center experience from a cohort of 110 consecutive cases (2020) Int J Endocrinol, 2020, p. 1491475; Chung, C., Management of neuroendocrine tumors (2016) Am J Health Syst Pharm, 73 (21), pp. 1729-1744; Keeney, S., Hasson, F., McKenna, H.P., A critical review of the Delphi technique as a research methodology for nursing (2001) Int J Nurs Stud, 38 (2), pp. 195-200
PY - 2020
Y1 - 2020
N2 - Background: Somatostatin receptor ligands including octreotide LAR are first-line therapy in locally advanced or metastatic NETs that are nonresectable and well differentiated and are recommended as first-line therapy in functioning and in G1/low G2 nonfunctioning NETs. However, several questions remain that are not adequately addressed in current guidelines regarding its use in clinical scenarios in which the tumor progresses. These include use of nonconventional doses or schedules of octreotide LAR in tumors with hormonal symptoms or showing clinical-radiological progression, administration in combination with everolimus, peptide receptor radionuclide therapy, and chemotherapy, following first-line treatment with octreotide LAR. Methods: An expert panel was gathered to obtain consensus using Delphi methodology on a series of statements regarding further administration of octreotide LAR after its use in first-line therapy in these settings in patients who experience disease progression. Results: Consensus was reached for 8 of the 10 statements proposed in the above clinical scenarios; consensus was not achieved for two statements. Conclusions: The present statements aim to fill current gaps in treatment guidelines by providing recommendations based on expert consensus in clinical settings in which patients progress following first-line therapy with octreotide LAR. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
AB - Background: Somatostatin receptor ligands including octreotide LAR are first-line therapy in locally advanced or metastatic NETs that are nonresectable and well differentiated and are recommended as first-line therapy in functioning and in G1/low G2 nonfunctioning NETs. However, several questions remain that are not adequately addressed in current guidelines regarding its use in clinical scenarios in which the tumor progresses. These include use of nonconventional doses or schedules of octreotide LAR in tumors with hormonal symptoms or showing clinical-radiological progression, administration in combination with everolimus, peptide receptor radionuclide therapy, and chemotherapy, following first-line treatment with octreotide LAR. Methods: An expert panel was gathered to obtain consensus using Delphi methodology on a series of statements regarding further administration of octreotide LAR after its use in first-line therapy in these settings in patients who experience disease progression. Results: Consensus was reached for 8 of the 10 statements proposed in the above clinical scenarios; consensus was not achieved for two statements. Conclusions: The present statements aim to fill current gaps in treatment guidelines by providing recommendations based on expert consensus in clinical settings in which patients progress following first-line therapy with octreotide LAR. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
KW - advanced neuroendocrine tumors
KW - consensus
KW - delphi technique
KW - Octreotide LAR
KW - second-line therapy
KW - antineoplastic agent
KW - antineoplastic hormone agonists and antagonists
KW - everolimus
KW - octreotide
KW - delayed release formulation
KW - female
KW - human
KW - Italy
KW - male
KW - neuroendocrine tumor
KW - pathology
KW - practice guideline
KW - questionnaire
KW - Antineoplastic Agents, Hormonal
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Delayed-Action Preparations
KW - Everolimus
KW - Female
KW - Humans
KW - Male
KW - Neuroendocrine Tumors
KW - Octreotide
KW - Practice Guidelines as Topic
KW - Surveys and Questionnaires
U2 - 10.1080/14656566.2020.1810237
DO - 10.1080/14656566.2020.1810237
M3 - Article
VL - 21
SP - 2317
EP - 2324
JO - Expert Opin. Pharmacother.
JF - Expert Opin. Pharmacother.
SN - 1465-6566
IS - 18